Full Text of PDF (887k)
Article in Japanese
Abstract
Case Report
A case of large-cell neuroendocrine carcinoma under hemodialysis treated with amrubicin-adjusting drug dosage by pharmacokinetic monitoring
Masayuki Ishibashia Shigeo Hanadaa Eri Kashimab Shinko Suzukia Hisashi Takayaa Takeshi Fujiic,d Kazuma Kishia,d
aDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital
bDepartment of Pharmacology, Toranomon Hospital
cDepartment of Pathology, Toranomon Hospital
dOkinaka Memorial Institute for Medical Research
ABSTRACT
A 63-year-old woman with chronic renal failure on hemodialysis underwent a video-assisted thoracoscopic right lower lobectomy for pT2aN0M0 large-cell neuroendocrine carcinoma. Four cycles of adjuvant chemotherapy with cisplatin and etoposide were administered. After seven months, the patient developed a recurrence and received chemotherapy with amrubicin. During the first course of chemotherapy, the plasma concentrations of amrubicin and amrubicinol were measured. Because febrile neutropenia was observed as an adverse event, the dose of amrubicin administered was reduced to avoid drug toxicity with reference to the results of plasma concentrations. Dosage adjustment made it possible to treat this patient safely with amrubicin throughout four cycles of chemotherapy, and stable disease was achieved.
KEYWORDS
Large cell neuroendocrine carcinoma Amrubicin Hemodialysis Amrubicinol Area under the blood concentration time curve
Received 29 March 2013 ／ Accepted 1 Jul 2013
AJRS, 2(6): 788-793, 2013
Copyright © The Japanese Respiratory Society All Rights Reserved.